Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal bacteriophage transfer
- Development stage
- Phase 1
- Lead developer
- University of Copenhagen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal bacteriophage transfer (FBT), often referred to as fecal filtrate transfer (FFT), is an investigational microbiome-based therapy that involves the administration of a processed, bacterial-free filtrate derived from the feces of healthy donors. Unlike traditional fecal microbiota transplantation (FMT), the filtration process removes live bacteria, fungi, and parasites, resulting in a product that primarily contains the donor's virome (especially bacteriophages), metabolites, and proteins. The therapy aims to modulate the recipient's gut microbiome by utilizing bacteriophages to selectively infect and lyse specific bacterial populations, thereby shifting the microbial community toward a healthier state. It is currently being studied for its potential to enhance gastrointestinal maturation and prevent necrotizing enterocolitis (NEC) in preterm infants.
- Other names
- fecal filtrate transferFFTfecal virome transplantationFVT
Beyond the preview
Go deeper on fecal bacteriophage transfer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal bacteriophage transfer.